Hyaluronic acid/triamcinolone - Anika Therapeutics

Drug Profile

Hyaluronic acid/triamcinolone - Anika Therapeutics

Alternative Names: CINGAL; Sodium hyaluronate/triamcinolone hexacetonide

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anika Therapeutics
  • Class Analgesics; Fluorinated steroids; Glycosaminoglycans; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Osteoarthritis

Most Recent Events

  • 22 May 2017 Preregistration for Osteoarthritis in USA (Topical)
  • 22 May 2017 Anika Therapeutics initiates enrolment in a supplemental phase III trial for Osteoarthritis in European Union
  • 15 Feb 2017 Anika Therapeutics files an IND application with the US FDA for Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top